IBSA Institut Biochimique
As of the edition of 20 October 2026, IBSA Institut Biochimique runs 16 drugs, 15 of them marketed; it is on route A at 0 targets and on route B at 7 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 15 |
| Stopped | 1 |
| Total | 16 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Lidocaine | none listed | 2 |
| Acetylcysteine | none listed | 0 |
| Sildenafil | Ends 2030 (exclusivity) | 3 |
| Progesterone | none listed | 3 |
| Diclofenac | none listed | 7 |
| Heparin | none listed | 5 |
| Levothyroxine | none listed | 6 |
| Lorazepam | none listed | 1 |
| Glutamine | none listed | 0 |
| Betamethasone | none listed | 6 |
| Heparin sodium | none listed | 3 |
| Urofollitropin | none listed | 1 |
| Sulfadiazine | none listed | 0 |
| Chondroitin sulfate sodium | none listed | 0 |
| Dexfosfoserine | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 7 targets.
All 7 rows on route A or B
In the product7 company-target rows on route A or B; 4 are not shown here, and no score is.
See all 7 targets where IBSA Institut Biochimique needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Bones, joints and muscles: 3 trials led
- Urinary and reproductive: 1 trials led